Quantcast

Latest Friedreich's ataxia Stories

2008-11-06 09:00:45

WALTHAM, Mass., Nov. 6 /PRNewswire-FirstCall/ -- Repligen Corporation today reported results for the second quarter of fiscal year 2009, ended September 30, 2008.

2008-10-10 09:00:18

LIESTAL, SWITZERLAND--(Marketwire - Oct. 10, 2008) - Santhera Pharmaceuticals (SWX:SANN), a Swiss specialty pharmaceutical company with a focus on neuromuscular diseases, announced today the launch of CATENA(R) (idebenone) in Canada.

2008-09-16 12:00:10

WALTHAM, Mass., Sept. 16 /PRNewswire-FirstCall/ -- Repligen Corporation today reported publication of a preclinical study demonstrating that a novel histone deacetylase (HDAC) inhibitor improved disease symptoms in a transgenic animal model of Huntington's disease.

2008-08-07 09:01:05

WALTHAM, Mass., Aug. 7 /PRNewswire-FirstCall/ -- Repligen Corporation today reported results for the first quarter of fiscal year 2009, ended June 30, 2008.

2008-07-24 12:01:22

Santhera Pharmaceuticals has announced that Health Canada has approved SNT-MC17/idebenone, subject to certain conditions, for the treatment of Friedreich's Ataxia. Health Canada's decision is said to be the first marketing authorization worldwide for any Friedreich's Ataxia therapy.

2008-07-24 03:00:18

Santhera Pharmaceuticals (SWX: SANN), a Swiss specialty pharmaceutical company focused on neuromuscular diseases, announced today that Health Canada has approved with conditions SNT-MC17/idebenone for the treatment of Friedreich's Ataxia.

2008-06-18 21:00:23

MitoSciences has today released two new products for measuring Mitochondrial Biogenesis, a crucial biological process that is receiving increased attention due to its link to increased life span and greater resistance to disease.


Word of the Day
cespitose
  • Growing in low tufty patches.
The word 'cespitose' comes from a Latin word meaning 'turf'.
Related